Interim treatment change options for the COVID-19 endorsed by NHS England (09 April 2020)


Please find the link below to the most recent publication from NICE outlining Interim treatment change options during the COVID-19 pandemic issued on.  It is endorsed by NHS England. Some of options proposed for multiple myeloma are:

  • Allow oral pomalidomide with dexamethasone as second- or third-line therapy instead of intravenous treatments in patients previously treated with lenalidomide to reduce the need for chemotherapy and reduce admissions and risk of neutropenia.
  • Allow first-line lenalidomide and dexamethasone for transplant eligible myeloma patients in preference to regimens that require more hospital attendances and parenteral administrations to reduce toxicity of treatment and number of admissions required for treatment.
  • Allow second-line lenalidomide and dexamethasone for patients who have not been previously treated with bortezomib.

Please see link below to access the full document.

https://www.nice.org.uk/guidance/ng161/resources/interim-treatment-change-options-during-the-covid19-pandemic-endorsed-by-nhs-england-pdf-8715724381